Teriparatide Reconstitution Calculator

Yes. FDA-approved since 2002 as the first bone-forming (anabolic) osteoporosis drug, indicated for postmenopausal women and men at high fracture risk and for glucocorticoid-induced osteoporosis (RCT). Standard use is 20 µg subcutaneously daily. Extensive off-label use exists for hypoparathyroidism, medication-related osteonecrosis of the jaw (MRONJ), delayed fracture union, and perioperative bone optimization in spinal fusion surgery (RCT, observational).

Approved osteoporosis dose: 20 µg SC once daily; a 40 µg daily dose was also studied. A once-weekly 56.5 µg (product label) formulation reduced new vertebral fractures in the TOWER trial (RCT). Dosing is fixed, not body-weight-adjusted (practitioner consensus). For delayed-union long-bone fractures, 20 µg daily for 3 months achieved radiological union in 81.2% of patients at 12 weeks (prospective, uncontrolled). For hypoparathyroidism, 20 µg once daily or every other day maintains serum calcium and lowers phosphate (meta-analysis, observational). Fracture-healing evidence: in a prospective interventional study, 91% of treated osteoporotic fractures showed improved healing at 8 weeks vs 57% with placebo.

Yes. Oral bioavailability is negligible, and an intranasal spray showed ≤1% relative bioavailability vs subcutaneous injection in humans (RCT, pharmacokinetic). Injectable SC remains the only clinically practical route; oral robotic-pill and microsphere depot platforms remain preclinical (community protocol).

The approved safety window is a 24-month lifetime maximum. The anabolic response wanes after 6–12 months as markers and spine BMD gains plateau (RCT, mechanistic). Stopping without follow-up therapy loses gains: lumbar spine BMD falls ~2–3% within 2.5 years unless a bisphosphonate is started (RCT). Consolidation with an antiresorptive within 3 months is recommended, yet only 1 in 4 patients receives timely consolidation (observational). Note: prior bisphosphonate exposure modestly attenuates lumbar spine BMD response (meta-analysis).

Teriparatide is not approved during pregnancy, but in pregnancy- and lactation-associated osteoporosis (PLO) with fragility fractures, teriparatide/abaloparatide or romosozumab are the preferred first-choice anabolics per a multi-society position statement (expert consensus). Any pharmacotherapy in this setting should be paired with effective contraception; bisphosphonates are second-line due to placental transfer and skeletal retention.

Romosozumab outperformed teriparatide for vertebral fractures in CKD patients (HR 0.64) and any osteoporotic fracture in real-world women (HR 0.68) (observational). However, romosozumab carries higher cardiovascular reporting signals (MI ROR 2.38, stroke ROR 3.72), while teriparatide shows a favorable cardiovascular profile (pharmacovigilance). Teriparatide retains unique niches: fracture/non-union healing, MRONJ, hypoparathyroidism, and spinal-fusion adjuncts where pooled evidence supports lower proximal junctional kyphosis (OR 0.51) and reoperation (OR 0.36) (meta-analysis).

Nausea, headache, dizziness, and leg cramps are most common (RCT). Serum calcium rises transiently after each injection (~0.4 mg/dL peak at ~4 h), normalizing within 16–24 h; persistent hypercalcemia is uncommon, though teriparatide is the most frequently reported drug in FAERS hypercalcemia reports (2,539 cases; median onset 151 days for the musculo-skeletal drug class overall) (RCT, pharmacovigilance). Osteosarcoma: high-dose rat studies raised a black-box concern; FAERS shows a disproportionality signal vs all drugs (ROR 15.31) but not vs the romosozumab comparator, and no cases occurred among ~2,800 trial patients (RCT, pharmacovigilance).

Yes. Store unopened pens refrigerated (2–8°C, never freeze). After first use, a pen is generally stable at room temperature (≤25°C) for up to 28 days (community protocol). For travel, carry pens in an insulated cooler rather than checked luggage to avoid freezing; discard any pen left unrefrigerated more than 28 days after first use (practitioner consensus).